GILD

118.30

0.15% -0.18

Handel nachbörslich: 118.83 0.53 +0.45%

Gilead Sciences Inc (GILD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GILD? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$118.48

Offen:

$118.08

24-Stunden-Volumen:

4.46M

Relative Volume:

0.69

Marktkapitalisierung:

$146.79B

Einnahmen:

$28.80B

Nettoeinkommen (Verlust:

$6.31B

KGV:

23.53

EPS:

5.0273

Netto-Cashflow:

$9.37B

1W Leistung:

+0.04%

1M Leistung:

+5.12%

6M Leistung:

+11.94%

1J Leistung:

+37.85%

1-Tages-Spanne:

$117.07

$119.07

1-Wochen-Bereich:

$115.80

$119.33

52-Wochen-Spanne:

$85.60

$121.83

Gilead Sciences Inc Stock (GILD) Company Profile

Firmenname

Gilead Sciences Inc

Sektor

Healthcare (1137)

Branche

Drug Manufacturers - General (19)

Telefon

(650) 574-3000

Adresse

333 LAKESIDE DR, FOSTER CITY, CA

Mitarbeiter

17,600

Twitter

@GileadSciences

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

GILD's Discussions on Twitter

Vergleichen Sie GILD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GILD Gilead Sciences Inc	118.30	147.01B	28.80B	6.31B	9.37B	5.0273
LLY Lilly Eli Co	826.57	728.24B	53.26B	13.80B	-50.20M	15.08
JNJ Johnson Johnson	191.17	459.63B	92.15B	25.12B	18.18B	10.36
ABBV Abbvie Inc	226.22	404.77B	58.33B	3.73B	18.24B	2.1013
NVS Novartis Ag Adr	129.97	252.16B	53.40B	13.68B	16.89B	6.8864
MRK Merck Co Inc	84.11	211.56B	63.43B	16.42B	14.72B	6.4861

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-19	Hochstufung	Daiwa Securities	Neutral → Outperform
2025-08-08	Hochstufung	Truist	Hold → Buy
2025-07-25	Hochstufung	Needham	Hold → Buy
2025-04-22	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-03-04	Bestätigt	Oppenheimer	Outperform
2025-02-18	Hochstufung	Deutsche Bank	Hold → Buy
2025-02-13	Hochstufung	DZ Bank	Hold → Buy
2025-01-10	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Fortgesetzt	BofA Securities	Buy
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Buy
2024-11-08	Herabstufung	Maxim Group	Buy → Hold
2024-10-21	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-17	Eingeleitet	Bernstein	Outperform
2024-10-07	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-07-08	Hochstufung	Raymond James	Mkt Perform → Outperform
2024-05-01	Bestätigt	Maxim Group	Buy
2024-04-24	Hochstufung	HSBC Securities	Reduce → Hold
2024-02-22	Herabstufung	Truist	Buy → Hold
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-09-08	Hochstufung	BofA Securities	Neutral → Buy
2023-09-06	Eingeleitet	HSBC Securities	Reduce
2023-07-24	Bestätigt	Barclays	Equal Weight
2023-05-16	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Fortgesetzt	Piper Sandler	Overweight
2023-01-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Fortgesetzt	BofA Securities	Neutral
2022-12-09	Herabstufung	DZ Bank	Buy → Hold
2022-10-31	Hochstufung	Barclays	Underweight → Equal Weight
2022-10-28	Bestätigt	BMO Capital Markets	Market Perform
2022-10-28	Bestätigt	Cowen	Outperform
2022-10-28	Bestätigt	JP Morgan	Overweight
2022-10-28	Bestätigt	Jefferies	Buy
2022-10-28	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-28	Bestätigt	RBC Capital Mkts	Outperform
2022-10-28	Hochstufung	Truist	Hold → Buy
2022-10-28	Bestätigt	Wells Fargo	Equal Weight
2022-10-04	Hochstufung	JP Morgan	Neutral → Overweight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-05-23	Eingeleitet	SVB Leerink	Mkt Perform
2022-02-28	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-02-02	Bestätigt	BMO Capital Markets	Outperform
2022-02-02	Bestätigt	BofA Securities	Neutral
2022-02-02	Bestätigt	RBC Capital Mkts	Outperform
2022-02-02	Bestätigt	Truist	Hold
2022-02-02	Bestätigt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Argus	Hold → Buy
2022-01-06	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Fortgesetzt	Wells Fargo	Equal Weight
2021-12-06	Eingeleitet	Goldman	Neutral
2021-11-19	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Fortgesetzt	Piper Sandler	Neutral
2021-10-20	Fortgesetzt	Cowen	Outperform
2021-07-30	Bestätigt	BMO Capital Markets	Market Perform
2021-07-30	Bestätigt	RBC Capital Mkts	Outperform
2021-04-01	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-03-30	Hochstufung	Redburn	Neutral → Buy
2021-01-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	Hochstufung	Guggenheim	Neutral → Buy
2020-11-03	Fortgesetzt	Morgan Stanley	Equal-Weight
2020-10-28	Eingeleitet	UBS	Neutral
2020-09-30	Fortgesetzt	Jefferies	Buy
2020-09-15	Hochstufung	Maxim Group	Hold → Buy
2020-07-31	Bestätigt	Credit Suisse	Neutral
2020-07-31	Bestätigt	Morgan Stanley	Equal-Weight
2020-07-31	Bestätigt	Piper Sandler	Overweight
2020-07-31	Bestätigt	RBC Capital Mkts	Outperform
2020-07-31	Bestätigt	SunTrust	Hold
2020-07-31	Bestätigt	Wells Fargo	Equal Weight
2020-07-20	Hochstufung	Credit Suisse	Underperform → Neutral
2020-06-03	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-05-26	Hochstufung	SunTrust	Sell → Hold
2020-05-01	Herabstufung	JP Morgan	Overweight → Neutral
2020-05-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-05-01	Herabstufung	SunTrust	Hold → Sell
2020-04-27	Herabstufung	UBS	Buy → Neutral
2020-04-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-04-20	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-17	Herabstufung	CFRA	Hold → Sell

Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

Oct 15, 2025

Gilead presents new HIV research data at EACS 2025 – driving scientific innovation in treatment and prevention - European AIDS Treatment Group

Oct 15, 2025

Gilead to present data on potential first weekly oral treatment for HIV - Clinical Trials Arena

Oct 15, 2025

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials - Benzinga

Oct 15, 2025

Gilead highlights HIV pipeline at European AIDS Conference - The Pharma Letter

Oct 15, 2025

Sjogren’s Syndrome Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Gilead Sciences, Incyte Corp, Novartis, GlaxoSmithKline, Janssen Research & Development, LLC - Barchart.com

Oct 15, 2025

ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial - Seeking Alpha

Oct 15, 2025

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention - BioSpace

Oct 15, 2025

Gilead (GILD) Showcases Advances in HIV Research at European AIDS Conference - GuruFocus

Oct 15, 2025

Gilead presents new HIV research data at European AIDS Conference - StreetInsider

Oct 15, 2025

Oct 14, 2025

Chinese Research Org. Says Gilead Infringed COVID Patent - Law360

Oct 14, 2025

Gilead and Arcus see survival boost with gastric cancer combo - The Pharma Letter

Oct 14, 2025

Oct 13, 2025

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga

Oct 13, 2025

Gilead to present promising data for Trodelvy in breast cancer at ESMO - Investing.com

Oct 13, 2025

Gilead to present Trodelvy breast cancer data at ESMO 2025 - StreetInsider

Oct 13, 2025

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades' - Benzinga

Oct 13, 2025

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025 - Business Wire

Oct 13, 2025

Yousif Capital Management LLC Sells 2,855 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 13, 2025

Survival data boost prospects for Gilead, Arcus TIGIT drug in gastric cancer - firstwordpharma.com

Oct 13, 2025

ADAPT: Accelerating Disability Awareness & Progress Together - Gilead Sciences

Oct 13, 2025

Oct 12, 2025

OFI Invest Asset Management Sells 86,817 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 12, 2025

Transcendent Capital Group LLC Invests $432,000 in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 12, 2025